Exciting Research Shows Vaccines Effective in Treating Childhood Cancer
End Kids Cancer named as a supporter of important new cancer research.
SAN LUIS OBISPO, Calif., Dec. 20, 2018 /PRNewswire-PRWeb/ -- At the 2018 Advances in Neuroblastoma Research (ANR) conference, held in San Francisco, leading childhood cancer researchers presented their most recent findings on the treatment of neuroblastoma, the most common type of cancer affecting infants and young children. One of the most anticipated presentations featured the research of Dr. Brian Kushner and Dr. Shakeel Modak of Memorial Sloan-Kettering Cancer Center. They utilized a vaccine that presented an 80% reduction in relapse for Neuroblastoma patients in remission over a period of six years. This equates to an increased patient survival rate, from 30% to 54%.
Not only was the efficacy of the treatment greatly improved, the non-invasive treatment, in the form of seven shots of a non-toxic vaccine, presented no short or long-term, life-threatening side effects. Compared to current treatments for neuroblastoma, which include chemotherapy, radiation, and other invasive treatments that can result in trauma and potentially life-long and life-threatening side effects, this new vaccine-based treatment is able to avoid these side-affects.
End Kids Cancer is very proud to be named as a supporter of this very important advancement, which was possible, in part, due to the support of our donors. Here at End Kids Cancer, we are extremely grateful to our donors that helped make this research happen.
If you are not currently a supporter, please consider a donation and help End Kids Cancer.
For a free e-book on how to find the best treatment for you or a loved one, download "Steps of Hope" here.
http://www.EndKidsCancer.org
805-550-7682
Frank(at)EndKidsCancer.org
SOURCE End Kids Cancer
Share this article